Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients

Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 1995-10, Vol.6 (8), p.755-758
Hauptverfasser: Chang, J., Sharpe, J. C., A'Hern, R. P., Fisher, C., Blake, P., Shepherd, J., Gore, M. E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 758
container_issue 8
container_start_page 755
container_title Annals of oncology
container_volume 6
creator Chang, J.
Sharpe, J. C.
A'Hern, R. P.
Fisher, C.
Blake, P.
Shepherd, J.
Gore, M. E.
description Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy
doi_str_mv 10.1093/oxfordjournals.annonc.a059312
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77775636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77775636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</originalsourceid><addsrcrecordid>eNpVkFFrFDEUhYModW39CcI8aJ86azJ3kkwEH2SxtlixoBXxJdzJJDp1JtkmM0v7703ZYcG8XMg5J_fkI-QNo2tGFbwN9y7E7jbM0eOQ1uh98GaNlCtg1ROyYlyosqE1e0pWVFVQSg71c_IipVtKqVCVOiJHDW8UZWxFbjYYTe9DyiOMWARXTH9sEXYYH94Vl970nfXGnhXbGH5nW5_OiilanEbrpwJ9V6Q57vodDo_RLU59vk8n5JnL5ezLZR6Tm_OP3zcX5dXXT5ebD1elqetqKisqc-3WtI3i3BgjbCclMtc41xmOxjELNSoDKBHaRkBrFDijpLCu7VoFx-R0_25udzfbNOmxT8YOA3ob5qRlPlyAyMb3e6OJIaVond7Gfsx_1IzqR6z6f6x6j1UvWHP-1bJobkfbHdILx6y_XnRMBgcXMZNLBxsIBZRDtpV7W58me3-QMf7VQoLk-uLnL_1ZifrbF7jWP-Af4BqaNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77775636</pqid></control><display><type>article</type><title>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Chang, J. ; Sharpe, J. C. ; A'Hern, R. P. ; Fisher, C. ; Blake, P. ; Shepherd, J. ; Gore, M. E.</creator><creatorcontrib>Chang, J. ; Sharpe, J. C. ; A'Hern, R. P. ; Fisher, C. ; Blake, P. ; Shepherd, J. ; Gore, M. E.</creatorcontrib><description>Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/oxfordjournals.annonc.a059312</identifier><identifier>PMID: 8589011</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinosarcoma - epidemiology ; Carcinosarcoma - pathology ; Carcinosarcoma - therapy ; carcinosarcoma ovary ; Combined Modality Therapy ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Incidence ; management ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Ovarian Neoplasms - epidemiology ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Prognosis ; prognostic factors ; Retrospective Studies ; Survival Rate ; Tumors</subject><ispartof>Annals of oncology, 1995-10, Vol.6 (8), p.755-758</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</citedby><cites>FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3693053$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8589011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Sharpe, J. C.</creatorcontrib><creatorcontrib>A'Hern, R. P.</creatorcontrib><creatorcontrib>Fisher, C.</creatorcontrib><creatorcontrib>Blake, P.</creatorcontrib><creatorcontrib>Shepherd, J.</creatorcontrib><creatorcontrib>Gore, M. E.</creatorcontrib><title>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinosarcoma - epidemiology</subject><subject>Carcinosarcoma - pathology</subject><subject>Carcinosarcoma - therapy</subject><subject>carcinosarcoma ovary</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Incidence</subject><subject>management</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - epidemiology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkFFrFDEUhYModW39CcI8aJ86azJ3kkwEH2SxtlixoBXxJdzJJDp1JtkmM0v7703ZYcG8XMg5J_fkI-QNo2tGFbwN9y7E7jbM0eOQ1uh98GaNlCtg1ROyYlyosqE1e0pWVFVQSg71c_IipVtKqVCVOiJHDW8UZWxFbjYYTe9DyiOMWARXTH9sEXYYH94Vl970nfXGnhXbGH5nW5_OiilanEbrpwJ9V6Q57vodDo_RLU59vk8n5JnL5ezLZR6Tm_OP3zcX5dXXT5ebD1elqetqKisqc-3WtI3i3BgjbCclMtc41xmOxjELNSoDKBHaRkBrFDijpLCu7VoFx-R0_25udzfbNOmxT8YOA3ob5qRlPlyAyMb3e6OJIaVond7Gfsx_1IzqR6z6f6x6j1UvWHP-1bJobkfbHdILx6y_XnRMBgcXMZNLBxsIBZRDtpV7W58me3-QMf7VQoLk-uLnL_1ZifrbF7jWP-Af4BqaNA</recordid><startdate>19951001</startdate><enddate>19951001</enddate><creator>Chang, J.</creator><creator>Sharpe, J. C.</creator><creator>A'Hern, R. P.</creator><creator>Fisher, C.</creator><creator>Blake, P.</creator><creator>Shepherd, J.</creator><creator>Gore, M. E.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951001</creationdate><title>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</title><author>Chang, J. ; Sharpe, J. C. ; A'Hern, R. P. ; Fisher, C. ; Blake, P. ; Shepherd, J. ; Gore, M. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinosarcoma - epidemiology</topic><topic>Carcinosarcoma - pathology</topic><topic>Carcinosarcoma - therapy</topic><topic>carcinosarcoma ovary</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Incidence</topic><topic>management</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - epidemiology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Sharpe, J. C.</creatorcontrib><creatorcontrib>A'Hern, R. P.</creatorcontrib><creatorcontrib>Fisher, C.</creatorcontrib><creatorcontrib>Blake, P.</creatorcontrib><creatorcontrib>Shepherd, J.</creatorcontrib><creatorcontrib>Gore, M. E.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, J.</au><au>Sharpe, J. C.</au><au>A'Hern, R. P.</au><au>Fisher, C.</au><au>Blake, P.</au><au>Shepherd, J.</au><au>Gore, M. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>1995-10-01</date><risdate>1995</risdate><volume>6</volume><issue>8</issue><spage>755</spage><epage>758</epage><pages>755-758</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>8589011</pmid><doi>10.1093/oxfordjournals.annonc.a059312</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 1995-10, Vol.6 (8), p.755-758
issn 0923-7534
1569-8041
language eng
recordid cdi_proquest_miscellaneous_77775636
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinosarcoma - epidemiology
Carcinosarcoma - pathology
Carcinosarcoma - therapy
carcinosarcoma ovary
Combined Modality Therapy
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Incidence
management
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Staging
Ovarian Neoplasms - epidemiology
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Prognosis
prognostic factors
Retrospective Studies
Survival Rate
Tumors
title Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carcinosarcoma%20of%20the%20ovary:%20Incidence,%20prognosis,%20treatment%20and%20survival%20of%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Chang,%20J.&rft.date=1995-10-01&rft.volume=6&rft.issue=8&rft.spage=755&rft.epage=758&rft.pages=755-758&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/oxfordjournals.annonc.a059312&rft_dat=%3Cproquest_cross%3E77775636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77775636&rft_id=info:pmid/8589011&rfr_iscdi=true